ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York on Tuesday, November 10, 2026, at 10:40 a.m. EST, the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 7:00 a.m. EST and the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, 2026, at 4:30 p.m. EST.
Event: Stifel 2026 Healthcare Conference
Date: Tuesday, November 10, 2026
Time: 10:40 a.m. EST
Event: Jefferies Global Healthcare Conference
Date: Tuesday, November 17, 2026
Time: 7:00 a.m. EST
Event: Piper Sandler 38th Annual Healthcare Conference
Date: Tuesday, December 1, 2026
Time: 4:30 p.m. EST
A live and archived webcast of the fireside chats will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
[email protected]
SOURCE TransMedics Group, Inc.